Brentuximab vedotin

• Description :

  Brentuximab vedotin (SGN-35) is a CD30-targeting antibody-active molecule conjugate (ADC) that combines a CD30 monoclonal antibody with the microtubule disrupting agent monomethylauristatin E for the study of lymphoma.

• Stability :

  ≥ 2 years

• Purity :

  >98% (HPLC)

• Weight :

  Approximately 145.58 kDa.

• Molecular Formula :

  ——

• Notes :

  Research use only, not for human use.

• Receptor :

  Antibody-Drug Conjugates (ADCs)

• CAS Number :

  914088-09-8